CN108853123A - Application of the aspirin in colon cancerous precaution or treatment - Google Patents

Application of the aspirin in colon cancerous precaution or treatment Download PDF

Info

Publication number
CN108853123A
CN108853123A CN201810608490.1A CN201810608490A CN108853123A CN 108853123 A CN108853123 A CN 108853123A CN 201810608490 A CN201810608490 A CN 201810608490A CN 108853123 A CN108853123 A CN 108853123A
Authority
CN
China
Prior art keywords
aspirin
group
ticagrelor
cell
colon cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201810608490.1A
Other languages
Chinese (zh)
Other versions
CN108853123B (en
Inventor
周红霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Su Binbin
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201810608490.1A priority Critical patent/CN108853123B/en
Publication of CN108853123A publication Critical patent/CN108853123A/en
Application granted granted Critical
Publication of CN108853123B publication Critical patent/CN108853123B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to application of the aspirin in colon cancerous precaution or treatment, further relate to the pharmaceutical composition comprising aspirin.The degree that aspirin can make platelet activation rate reduce is alleviated, and the transfer ability and invasive ability of tumour cell are suppressed.Present invention research aspirin provides new thinking to the bioelectric detecting mechanism of colon cancer tumours microenvironment and to the medicinal effects of colon cancer for the depth research and development of aspirin and the clinical treatment of colon cancer.

Description

Application of the aspirin in colon cancerous precaution or treatment
Technical field
The present invention relates to biomedicine fields, and in particular to application of the aspirin in colon cancerous precaution or treatment.
Background technique
Aspirin (Aspirin, acetylsalicylic acid) is salicylic derivative, material property be a kind of white crystals or Crystalline powder, odorless or micro-strip acetic acid is smelly, is slightly soluble in water, is soluble in ethyl alcohol, dissolves in ether, chloroform, aqueous solution is in acidity. Early in 1853, people synthesized acetylsalicylic acid by salicylic acid and acetic anhydride for the first time.Between several years, people gradually have found acetyl Salicylic acid has the effects that good anti-inflammatory, antipyretic analgesic.Until 1899, acetylsalicylic acid started to be widely applied to face Bed, and it is renamed as aspirin (Aspirin).
Aspirin was after clinical application in over one hundred year, it has proved that alleviating slight or moderate pain, such as toothache, head Bitterly, the effect of neuralgia, DOMS, arthralgia and dysmenorrhea is preferable, is equally used for bringing down a fever for the fever diseases such as flu, influenza Deng.The derivative drug of aspirin emerges one after another at present, is widely used in the clinical treatment of antipyretic analgesic.Discovered in recent years Ah Si Woods has inhibiting effect to platelet aggregation, can prevent the formation of thrombus, clinically for preventing transient ischemic attack, the heart The formation of thrombus after flesh infarct, heart valve prosthesis and venous fistula or other operations.
Colon cancer is the common malignant tumor of digestive tract for betiding colon site, and usually morbidity is in rectum and sigmoid colon Intersection.With the disease incidence highest of 40~50 years old age group, the ratio between men and women is 2~3：1.Disease incidence accounts for the of gastroenteric tumor 3.Colon cancer is broadly divided into gland cancer, mucinous adenocarcinoma, undifferentiated carcinoma.General form is in polypoid, ulcer type etc..Colon cancer can edge Intestinal wall, which is gone in ring, to be developed, and is indulged diameter or more sprawling along intestinal tube or is infiltrated to intestinal wall deep layer, except through lymphatic vessel, blood flow shifts and local Invasion It outside, can also be to intraperitoneal plantation or along suture, cut sides diffusion transfer.Patients with chronic colitis, polyp of colon patient, Nan Xingfei Fat persons etc. are Susceptible population.
In recent years, people start to find that aspirin has certain clinical effectiveness in preventing, treating for Partial tumors. But aspirin is for also rarely having document report in the preventing, treating of colon cancer.Aspirin is studied in the present invention to tie Intestinal cancer prevention or application method and therapeutic effect in treatment, provide a new thinking for clinical treatment colon cancer.
Summary of the invention
The present invention aiming at the shortcomings in the prior art, is related to application of the aspirin in treatment of colon cancer.
The present invention provides aspirin in preparation for preventing or treating with colon cancer or with colon cancer risk Purposes in the drug of patient.
In an aspect, dosage of the aspirin in the patient is 10~100mg/kg/d；It is preferred that 50mg/kg/d.
In an aspect, content of the aspirin in the drug is 20~500 μM；It is preferred that 50~300 μM.
In an aspect, the drug further includes platelet aggregation inhibitor；It is preferred that ticagrelor.
In an aspect, dosage of the platelet aggregation inhibitor in the patient is 5~50mg/kg/d；It is excellent Select 10mg/kg/d.
In an aspect, content of the platelet aggregation inhibitor in the drug is 5~50 μM；It is preferred that 20 μM.
In an aspect, in the drug, the quality proportioning of the aspirin and both ticagrelors is (10~2)：1, preferably 5：1, or both mol ratio is (20~5)：1, preferably 10：1.
In an aspect, after the patient receives the drug, colon cancer tumours are suppressed.
In an aspect, after the patient receives the drug, the reduction degree of the patient's weight slows down, described The degree that Platelet activation rate reduces is alleviated, and the expression of HIF-1 α, GLUT-1 and ALDH-1 are lowered in the patient, described The transfer ability and invasive ability of the tumour cell of patient are suppressed.
In an aspect, the patient is selected from people or non-human animal；It is preferred that non-human animal；More preferable mouse.
The present invention provides a kind of pharmaceutical compositions, and it includes aspirin and pharmaceutically acceptable carrier.
In an aspect, the content of the aspirin is 20~500 μM；It is preferred that 50~300 μM.
In an aspect, described pharmaceutical composition also includes platelet aggregation inhibitor；It is preferred that ticagrelor.
In an aspect, content of the platelet aggregation inhibitor in described pharmaceutical composition is 5~50 μM；It is excellent Select 20 μM.
In an aspect, in described pharmaceutical composition, the quality of both the aspirin and described ticagrelor Proportion is (10~2)：1, preferably 5：1, or both mol ratio is (20~5)：1, preferably 10：1.
In an aspect, pharmaceutical preparation can be made in described pharmaceutical composition according to conventional methods.In production process, preferably The aspirin is mixed with pharmaceutically acceptable carrier or is diluted with carrier.It when the carrier serves as a diluent, can be with For solid, semisolid or liquid.Preparation is selected from tablet, pill, pulvis, capsule, suspension, emulsion, solution, aerosol, note It penetrates with forms such as solution.
The positive effect of the present invention includes：Aspirin can inhibit platelet activation, receive the shifting of aspirin for treatment Tumor mouse is planted, compared to the control group, the reduction degree of weight slows down, and the degree that platelet activation rate reduces is alleviated, HIF-1 α, The expression of GLUT-1 and ALDH-1 is lowered, and the transfer ability and invasive ability of tumour cell are suppressed.Present invention research Ah Si Woods studies influence of the aspirin to colon cancer medicinal effects, existing to the bioelectric detecting mechanism of colon cancer tumours microenvironment Have in technology and be rarely reported, this has opened up new Research Prospects for the treatment of colon cancer, is depth research and development and the knot of aspirin The clinical treatment of intestinal cancer provides new thinking.
Detailed description of the invention
Fig. 1：The changes of weight of each group mouse 7-31d after tumor inoculation.Control group is blank group, i.e., is not inoculated with swollen Tumor+without drug-treated；TI group is control group, i.e. transplantable tumor+drug-treated is not added；TI+Aspirin group is that aspirin is complete Journey administration group, i.e., before transplantable tumor+transplanting in after aspirin stomach-filling processing；TI+Ticagrelor group be ticagrelor whole process to Medicine group, i.e., before transplantable tumor+transplanting in after ticagrelor stomach-filling processing；TI+Aspirin+Ticagrelor group is aspirin+replace Ge Ruiluo whole process administration group, i.e., before transplantable tumor+transplanting in after the processing of aspirin+ticagrelor stomach-filling.TI represents tumor inoculation。
Fig. 2：The changes of weight of each group mouse 7-31d after tumor inoculation.Control group, TI group, TI+Aspirin group, TI+Ticagrelor group, TI+Aspirin+Ticagrelor group, the meaning of TI are consistent with preceding figure.Note：*p< 0.05vs.Control,#p<0.05vs.TI, not marking indicates p>0.05.
Fig. 3：Each group mice-transplanted tumor Microvascular architecture (400 ×).TI group, TI+Aspirin group, TI+Ticagrelor Group, TI+Aspirin+Ticagrelor group, the meaning of TI are consistent with preceding figure.
Fig. 4：Each group mice-transplanted tumor vessel branch number and blood vessel total length.TI group, TI+Aspirin group, TI+ Ticagrelor group, TI+Aspirin+Ticagrelor group, the meaning of TI are consistent with preceding figure.
Fig. 5：Each group mouse flow cytometer detection platelet activation rate result.Control group, TI group, TI+Aspirin group, TI+ Ticagrelor group, TI+Aspirin+Ticagrelor group, the meaning of TI are consistent with preceding figure.
Fig. 6：Each group mouse platelets activation rate.Control group, TI group, TI+Aspirin group, TI+Ticagrelor group, TI+Aspirin+Ticagrelor group, the meaning of TI are consistent with preceding figure.Note：*p<0.05vs.Control, * * p< 0.01vs.Control,#p<0.05vs.TI, not marking indicates p>0.01.
Fig. 7：Each group mouse platelets activation rate.Control group, TI group, TI+Aspirin group, TI+Ticagrelor group, TI+Aspirin+Ticagrelor group, the meaning of TI are consistent with preceding figure.Note：*p<0.05vs.Control, * * p< 0.01vs.Control,#p<0.05vs.TI, not marking indicates p>0.01.
Fig. 8：Each group mouse platelets activation rate.Control group, TI group, TI+Aspirin group, TI+Ticagrelor group, TI+Aspirin+Ticagrelor group, the meaning of TI are consistent with preceding figure.Note：*p<0.05vs.Control, * * p< 0.01vs.Control,##p<0.01vs.TI, not marking indicates p>0.01.
Fig. 9：Each group mouse platelets activation rate.Control group, TI group, TI+Aspirin group, TI+Ticagrelor group, TI+Aspirin+Ticagrelor group, the meaning of TI are consistent with preceding figure.Note：*p<0.05vs.Control, * * p< 0.01vs.Control,##p<0.01vs.TI, not marking indicates p>0.01.
Figure 10：Each group mouse is at tumor tissue CD41 and CD62P Double immunofluorescence coloration result (400 ×).Group 2 is Control group, Group 3 are aspirin whole process administration group, and Group 4 is ticagrelor whole process administration group, and Group 5 is Ah Si Woods+ticagrelor whole process administration group.
Figure 11：Each group mouse immune histochemical staining result (400 ×).TI group, TI+Aspirin group, TI+Ticagrelor Group, TI+Aspirin+Ticagrelor group, the meaning of TI are consistent with preceding figure.
Figure 12：Dyeing site representativeness picture (400 ×), GULT1 (number 5-20,400 ×, cell membrane coloring).
Figure 13：Dyeing site representativeness picture (400 ×), HIF1- α (number 3-2,400 ×, nucleus coloring).
Figure 14：Dyeing site representativeness picture (400 ×), ALDH-1 (number 3-1,400 ×, cytoplasm coloring).
Figure 15：Group of cells transfer ability statistical chart.Control group：Colon cancer cell+10%PRP group；Aspirin- Low group：Colon cancer cell+10%PRP+ aspirin low dose group；Aspirin-high group：Colon cancer cell+10%PRP+ Aspirin high dose group；Ticagrelor group：Colon cancer cell+10%PRP+ ticagrelor group；Aspirin+ Ticagrelor group：Colon cancer cell+10%PRP+ aspirin group+ticagrelor group.Note：* p is indicated<0.05；* indicates p< 0.01；* * indicates p<0.001；* * * indicates p<0.0001.
Figure 16：Group of cells invasive ability statistical chart.Control group, Aspirin-low group, Aspirin-high group, Ticagrelor group, the meaning of Aspirin+Ticagrelor group are consistent with preceding figure.Note：* p is indicated<0.05；* indicates p< 0.01；* * indicates p<0.001；* * * indicates p<0.0001.
Figure 17：Flow cytometer detection different disposal tumour cell ALDH-1 expression.Control group, Aspirin-low group, Aspirin-high group, Ticagrelor group, the meaning of Aspirin+Ticagrelor group are consistent with preceding figure.Note：* p is indicated< 0.05；* indicates p<0.01；* * indicates p<0.001；* * * indicates p<0.0001.
Specific embodiment
Experimental material used in following experimental methods unless otherwise instructed, can be obtained easily from commercial company.? In the case where spirit of that invention, those skilled in the art combine well-known technique, and many modifications can be made to the present invention, Such modification is also fallen within protection scope of the present invention.
The experiment of embodiment 1, aspirin to colon cancer transplantable tumor microenvironment
One, experimental material
Experimental animal：BALB/C nude mouse, 6-8 week old, female, weight 25-30g.
Experimental cell：Human large intestine cancer HCT116 cell line is placed in 10% fetal calf serum RPMI1640 culture solution, 37 DEG C, 5%CO2Culture, 2-3d are passed on 1 time, and logarithmic growth phase cell is for testing.
Medicine preparation：(1) aspirin is dissolved in 0.9% physiological saline, is configured to 1.0mg/ml solution.(2) auspicious for lattice Lip river is dissolved in 0.9% physiological saline 500ml, is configured to 1mg/ml solution.
Two, experimental group
1, blank group：The not nude mice of inoculated tumour+without drug-treated
2, control group：Transplantation tumor+drug-treated is not added
3, aspirin whole process administration group：Aspirin stomach-filling processing after in front of transplantation tumor+inoculation.
4, ticagrelor whole process administration group：Ticagrelor stomach-filling processing after in front of transplantation tumor+inoculation.
5, aspirin+ticagrelor whole process administration group：Aspirin+ticagrelor fills after in front of transplantation tumor+inoculation Stomach processing；The quality proportioning of aspirin and ticagrelor is 5：1.
Dosage regimen：Two kinds of drugs inoculation a few days ago 7d start to give drug stomach-filling daily, in inoculation day on the day of and it Afterwards, continue to give drug stomach-filling；The daily given low of aspirin is 50mg/kg/d；The daily given low of ticagrelor is 10mg/kg/d。
Tumor inoculation：BALB/C nude mice several are taken, HCT116 single cell suspension, quantity is subcutaneously injected in right side groin It is 5 × 106It is a.
Embodiment 2, mouse weight variation
One, experimental method
It is set empirically and carries out raising and drug-treated, measure and record mouse weight variation.Two, experimental result
Fig. 1, Fig. 2 are the changes of weight of each group mouse 7-31d after tumor inoculation.
The results show that comparing blank group normal mouse, the 7-17d after tumor inoculation, each group mouse weight is without significant difference (p>0.05)；When 21d, control group (TI) weight is substantially reduced (p<0.05)；When 24d, control group (TI) and ticagrelor are whole Administration group (TI+Ticagrelor) weight is substantially reduced (p<0.05)；When 28d, control group (TI group), the administration of aspirin whole process Group (TI+Aspirin) and ticagrelor whole process administration group (TI+Ticagrelor) weight are substantially reduced (p<0.05)；When 31d, Control group (TI group) and aspirin whole process administration group (TI+Aspirin) weight are substantially reduced (p<0.05).Compared to the control group (TI), each drug-treated group weight is without significant difference (p>0.05).
Embodiment 3, transplantable tumor Microvascular architecture and functional assessment
One, Preparatory work of experiment
Each experimental group randomly selects 6 nude mices respectively.Tail vein injection TRITC-dextran 100mg/kg.3h rear molding is quiet Arteries and veins injects FITC-lectin 10mg/kg.
Two, experimental method
After drug injection terminates 10min, cervical dislocation method puts to death mouse, takes out tumor mass, immediately frozen section (6 μm), laser Frozen section is observed under Laser Scanning Confocal Microscope, every slice randomly selects 5 unduplicated visuals field under high power lens (× 400) and adopts Collect image, by FITC-lectin green fluorescence assessment of vessel morphology, by leaking into extravascular TRITC-dextran's Area accounts for the ratio of the gross area, assesses vascular permeability.
Three, experimental result
Fig. 3 is each group mice-transplanted tumor Microvascular architecture, and Fig. 4 is each group mice-transplanted tumor vessel branch number and blood vessel total length.
The results show that comparing model control group (TI) mouse, aspirin whole process administration group (TI+Aspirin) mouse is moved Plant tumor vessel branch number and the non-limiting raising (p of blood vessel total length>0.05), ticagrelor whole process administration group (TI+ Ticagrelor) and aspirin and ticagrelor combine whole administration group (TI+Aspirin+Ticagrelor) mouse transplanting Tumor vessel branch number and the non-limiting reduction (p of blood vessel total length>0.05).
Area by leaking into extravascular TRITC-dextran accounts for the ratio of the gross area, assesses Vascular permeability situation, Picture display model control group (TI) mice-transplanted tumor vascular leakage is obvious, aspirin whole process administration group (TI+Aspirin) and Ticagrelor whole process administration group (TI+Ticagrelor) mice-transplanted tumor vascular leakage mitigates, aspirin and ticagrelor connection It is obvious to close whole administration group (TI+Aspirin+Ticagrelor) mice-transplanted tumor vascular leakage.
The detection of embodiment 4, platelet activation rate
One, Preparatory work of experiment
Each experimental group randomly selects 6 mouse punctures respectively and takes blood, is placed in anticoagulant tube containing EDTA living to detect blood platelet Rate.
Two, experimental method
2 test tubes are taken, 10 μ L FITC-CD41 antibody and 10 μ L PE-CD62p antibody are added in T1 test tube.Add in C1 test tube Enter corresponding isotype control Ab in T1 test tube, 0.5mL whole blood is added into 2 test tubes respectively, is protected from light and incubates at room temperature after mixing 20min is educated, 1.5mL PBS buffer solution is added, is mixed, centrifugation is abandoned supernatant and is separately added into again containing 4 DEG C of 1% paraformaldehyde 1mL of pre-cooling + 3 μ L Triton-100, are protected from light, will clean up before upper machine, upper machine testing interior for 24 hours.
Three, experimental result
Fig. 5 is each group mouse flow cytometer detection platelet activation rate result figure, and Fig. 6, Fig. 7, Fig. 8, Fig. 9 are that each group mouse blood is small Plate activation rate statistical chart.CD41+Cell proportion+CD62+Cell proportion is activated blood platelet cell proportion.
The results show that comparing blank group normal mouse, after tumor inoculation, model control group (TI), aspirin are whole Administration group (TI+Aspirin) and ticagrelor whole process administration group (TI+Ticagrelor) platelet activation rate significantly reduce (p< 0.05)；Aspirin and ticagrelor combine whole administration group (TI+Aspirin+Ticagrelor) platelet activation rate without aobvious Write difference (p>0.05).
Compared to model control group (TI) mouse, aspirin whole process administration group (TI+Aspirin) and ticagrelor whole process are given Medicine group (TI+Ticagrelor) platelet activation rate increases, but the not significant (p of difference>0.05)；Aspirin and replace lattice Rui Luo combines the extremely significant raising (p of whole administration group (TI+Aspirin+Ticagrelor) platelet activation rate<0.01).
The result shows that when aspirin and ticagrelor are respectively administered alone, to mouse platelets caused by tumor inoculation Activation rate reduction has relaxation effect, but not significant；And aspirin and the whole administration of ticagrelor joint can significantly alleviate tumour Mouse platelets activation rate caused by being inoculated with reduces.
Embodiment 5, the distribution of Immunofluorescence test tumor locus blood platelet
One, Preparatory work of experiment
Each experimental group randomly selects 6 mouse respectively, extracts tumor locus tissue, is placed on slide, spare.
Two, experimental method
1, serum is closed：Normal Goat Serum is added dropwise in slide tissue site, room temperature closes 30min.
2, blotting paper sops up confining liquid, does not wash, and FITC-CD41 antibody is added in slice, and after 4 DEG C are incubated overnight, PBS rinses 3 It is secondary, each 5min.
3, non-immune serum is added dropwise, 37 DEG C are incubated for 10 minutes.
4, PE-CD62p antibody is added dropwise, 4 DEG C are incubated overnight.PBS is rinsed 3 times, each 5min.
5, DAPI redyes nucleus.
6, water-soluble mountant mounting.
Two, experimental result
Figure 10 is the double mark coloration results of each group mouse tumor formation histogenic immunity fluorescence.Compared with Group2 group, Group3-5 group CD62P express reduce, wherein 5 groups of expression of Group are minimum.Compared with 2 groups of Group, the CD41 expression of Group3-5 group has Increased, wherein 5 groups of expression highests of Group.
CD62P is level of platelet activation mark, and CD41 is blood platelet aggregate level mark.From Figure 10 each group immunofluorescence Coloration result it can be concluded that, aspirin and ticagrelor can inhibit platelet activation, and can promote tumor locus blood Platelet aggregation.
The detection (immunohistochemistry) of embodiment 6, transplantable tumor tumor hypoxia, glycometabolism and tumor stem cell correlation marker
One, Preparatory work of experiment
Each experimental group randomly selects 6 mouse respectively, extracts tumor locus tissue samples, and positive piece is mouse liver group It knits.The above sample is first stored in neutral formalin after extraction, and sample carries out conventional dehydrating operations later, uses stone after the completion Wax embedding.
Two, experimental method
1, histotomy is taken, with dimethylbenzene and graded ethanol dewaxing aquation histotomy.
2,3%H2O210min is acted on, to block endogenous peroxydase；Distillation washing, PBS impregnate 3min.
3, antigen retrieval：The slice handled well, which is put into, fills citrate buffer (pH 6.0) pressure cooker, using high pressure Repairing method, the timing 2.5min since the steam bleeding, natural cooling, tap water shower to room temperature.
4, distillation washing 3min × 3 time, PBS wash 3min × 3 time；The closing of normal sheep serum working solution, is incubated at room temperature 30- 40min。
5, primary antibody (1 is added dropwise：100), 4 DEG C of refrigerators are incubated overnight；PBST washes 3min × 3 time；Corresponding secondary antibody, room temperature is added dropwise 30min；PBST washes 3min × 3 time.
6, DAB solution develops the color；Haematoxylin is redyed, and is originally washed, and indigo plant is returned in hydrochloride alcohol differentiation；It is dehydrated transparent rear mounting.
7, microscopically observation is taken pictures.
Three, experimental result
Figure 11 is each group mouse immune histochemical staining result picture, and table 1 is each group mouse immune histochemical staining outcome evaluation, Figure 12, Figure 13, Figure 14 are part dyeing site representativeness pictures.
The results show that Glut1 is primarily targeted for the cell membrane of tumour cell, and close to tumour by the tumour cell of film edge There is stronger expression compared to the cell of inside tumor.HIF1- α is primarily targeted for the nucleus of tumour cell, part cell Cytoplasm dyeing.ALDH-1 expression quantity is lower, and the cytoplasm of seldom Partial tumors cell is positive, the intravascular unknown cell positive in part.
Compared to model control group (TI) mouse, aspirin whole process administration group (TI+Aspirin), ticagrelor whole process are given Medicine group (TI+Ticagrelor) and aspirin and ticagrelor combine whole administration group (TI+Aspirin+Ticagrelor) The hypoxia markers (HIF-1 α) and glycometabolism label (GLUT-1) and tumor stem cell of plantation tumor mark (ALDH- in tumour body 1) expression decreases, but three treatment groups are between each other without significant difference.
The result shows that aspirin is administered alone, ticagrelor is administered alone, aspirin and ticagrelor joint are whole Administration can lower the expression of tumour HIF-1 α, GLUT-1 and ALDH-1, inhibit tumour.
Table 1, immunohistochemical staining outcome evaluation summarize
Embodiment 7, aspirin invade colon cancer cell under co-culture system and the influence of migration potential is tested
One, experimental group
1, colon cancer cell group：RPMI1640 culture medium+10%FBS+10%PRP (platelet rich plasma) group.
2, colon cancer cell+10%PRP+ aspirin low dose group：RPMI1640 culture medium+10%FBS+10%PRP+ 50 μM of aspirin.
3, colon cancer cell+10%PRP+ aspirin high dose group：RPMI1640 culture medium+10%FBS+10%PRP+ 300 μM of aspirin.
4, colon cancer cell+10%PRP+ ticagrelor group：+ 10%FBS+10%PRP+20 μM of PRMI1640 culture medium replaces Ge Ruiluo
5, colon cancer cell+10%PRP+ aspirin group+ticagrelor group：PRMI1640 culture medium+10%FBS+ + 20 μM of ticagrelors of 10%PRP+200 μM of aspirin two, experimental method
1, Transwell migration detection
(1) cell Transwell prepares.
(2) after infecting 48h, colon cancer cell prepares cell suspension.Cell density is adjusted to 1 × 106/mL。
(3) inoculating cell；Take 200 μ L of cell suspension that the cell Transwell is added；The training of 500 μ L, 10% serum is added in lower room Base is supported, in 37 DEG C of CO2Incubator culture is for 24 hours.
(4) cell Transwell is taken out, culture solution is discarded, PBS is washed 2 times, and the fixed 30min of formaldehyde air-dries cell.With 0.1% violet staining 20min, PBS are washed 3 times.
(5) it takes pictures observation.
2, Transwell invasion detection
(1) Matrigel thaws, 4 DEG C of defrostings.
(2) serum free medium is pressed：Matrigel=7：1 mixes as glue-line, is added drop-wise in cell with the 50 every holes μ L, in 37 DEG C of 1~2h of placement.
(3) upper and lower level working solution, upper layer (i.e. in cell) 200 μ L free serum culture basigamy cell liquid, 500 μ L of lower layer are configured 10% blood serum medium.
(4) it after Matrigel solidification, takes out and sucks the culture medium for not having solidification in supernatant.
(6) lower layer's working solution is added in 24 orifice plate of lower layer, is put into cell, upper layer working solution is added.
(7) small indoor culture solution is discarded after placing 20h or so, PBS is washed 2 times.
(8) remove the Matrigel and cell in upper chamber face, the fixed 20min of methanol, with 0.1% violet staining 15~ 20min, clear water are washed 3 times or more.
(9) it takes pictures observation.
3, the detection of colon cancer tumours stem cell labeling object ALDH-1
(1) it with 0.25% trypsin digestion cell, is collected after terminating digestion, 1500rpm is centrifuged 5min, discards supernatant, and collects Cell.
(2) it is resuspended cell 2 times with pre-cooling PBS, 1500rpm is centrifuged 5min, washs cell.
(3) being configured to concentration is 25 × 106Suspension cell, take 50 μ L cell suspensions, be separately added into 10%PRP, whole blood Platelet concentration 200 × 106Then ml adds the aspirin of respective concentration, react 15min under bar magnet stirring.
(4) CD61-FITC is marked：It after the CD41a-PE mixing of 5 μ L is added, is protected from light, is incubated at room temperature 15min.
(5) CD31-FITC is marked：It after the CD31-FITC mixing of 5 μ L is added, is protected from light, is incubated at room temperature 15min.
(6) it is resuspended cell 2 times with pre-cooling PBS, 1500rpm is centrifuged 5min, washs cell.
(7) 500 μ L PBS are added to be resuspended into single cell suspension, flow cytomery, software analysis.
Three, experimental result
1, Transwell detects colon cancer cell transfer ability
Figure 15 is cell migration ability statistical chart.The results show that 24 hour cells handle the time compared with Control group, Aspirin low concentration and high concentration, which have, inhibits cell migration effect, and high concentration inhibits cell migration ability higher than low dense Degree group, ticagrelor inhibitory effect are better than aspirin high concentration group.After 48 hour cells handle the time, each processing group inhibits thin Born of the same parents' transfer ability effect is more obvious.And aspirin group+ticagrelor group inhibitory effect is than individual ticagrelor group 8.7% is improved again.
2, Transwell detects colon cancer cell invasive ability
Figure 16 is cell invasion ability statistical chart.The results show that 24 hour cells handle the time compared with Control group, Aspirin low concentration and high concentration, which have, inhibits cell invasion effect, and high concentration inhibits cell invasion ability higher than low dense Degree group, ticagrelor inhibitory effect are better than aspirin low concentration group.After 48 hour cells handle the time, each processing group inhibits thin Born of the same parents' invasive ability effect is consistent with 24 hours.And aspirin group+ticagrelor group inhibitory effect is than individually replacing lattice auspicious Lip river group improves 6.8% again.
3, the detection of colon cancer tumours stem cell labeling object ALDH-1
Figure 17 is that concentration is 25 × 106Tumour cell flow cytometer detection ALDH-1 positive rate after different disposal statistics knot Fruit.Two figures can inhibit ALDH-1 protein expression with 48h processing time aspirin for 24 hours as the result is shown, and high dose Ah Department woods gets well than low-dosage aspirin inhibits ALDH-1 protein expression effect, and the 48h processing time is than effect for 24 hours It is good.Ticagrelor group, which is shown, inhibits ALDH-1 significant effect with 48h processing time ticagrelor for 24 hours, and 48h handles time ratio for 24 hours Effect will be got well.And aspirin group+ticagrelor group inhibitory effect improves 10.3% than individual ticagrelor group again.

Claims (10)

1. aspirin is in preparing the drug for preventing or treating the patient with colon cancer or with colon cancer risk Purposes.
2. purposes as described in claim 1, dosage of the aspirin in the patient is 10~100mg/kg/d；It is excellent Select 50mg/kg/d；Alternatively, content of the aspirin in the drug is 20~500 μM；It is preferred that 50~300 μM.
3. purposes as claimed in claim 1 or 2, the drug further includes platelet aggregation inhibitor；It is preferred that auspicious for lattice Lip river.
4. purposes as claimed in claim 4, dosage of the platelet aggregation inhibitor in the patient is 5~50mg/ kg/d；It is preferred that 10mg/kg/d；Alternatively, content of the platelet aggregation inhibitor in the drug is 5~50 μM；It is preferred that 20μM。
5. purposes as described in claim 3 or 4, in the drug, both the aspirin and described ticagrelor Quality proportioning is (10~2)：1, preferably 5：1；Or both mol ratio be (20~5)：1, preferably 10：1.
6. a kind of pharmaceutical composition, it includes aspirin and pharmaceutically acceptable carrier.
7. pharmaceutical composition as claimed in claim 6, the content of the aspirin is 20~500 μM；It is preferred that 50~300 μ M。
8. pharmaceutical composition as claimed in claims 6 or 7, described pharmaceutical composition also includes platelet aggregation inhibitor；It is excellent Select ticagrelor.
9. pharmaceutical composition as claimed in claim 8, the platelet aggregation inhibitor containing in described pharmaceutical composition Amount is 5~50 μM；It is preferred that 20 μM.
10. pharmaceutical composition as claimed in claim 8 or 9, in described pharmaceutical composition, the aspirin is replaced with described The quality proportioning of both Ge Ruiluo is (10~2)：1, preferably 5：1；Or both mol ratio be (20~5)：1, preferably 10： 1。
CN201810608490.1A 2018-06-13 2018-06-13 Application of aspirin in preventing or treating colon cancer Expired - Fee Related CN108853123B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810608490.1A CN108853123B (en) 2018-06-13 2018-06-13 Application of aspirin in preventing or treating colon cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810608490.1A CN108853123B (en) 2018-06-13 2018-06-13 Application of aspirin in preventing or treating colon cancer

Publications (2)

Publication Number Publication Date
CN108853123A true CN108853123A (en) 2018-11-23
CN108853123B CN108853123B (en) 2020-04-17

Family

ID=64338268

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810608490.1A Expired - Fee Related CN108853123B (en) 2018-06-13 2018-06-13 Application of aspirin in preventing or treating colon cancer

Country Status (1)

Country Link
CN (1) CN108853123B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020188547A1 (en) * 2019-03-21 2020-09-24 Universidade Nova De Lisboa Terpene based therapeutic deep eutectic system, method of obtaining and uses thereof
CN114848654A (en) * 2022-04-18 2022-08-05 武汉大学 Application of aspirin in preparation of medicine for causing tumor immunogenic cell death

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101229141A (en) * 2008-02-29 2008-07-30 常州制药厂有限公司 Aspirin sustained release tablet and preparing method thereof
CN104950112A (en) * 2015-06-11 2015-09-30 浙江大学 Application of FasL protein serving as biomarker to qualitative Aspirin sensitivity detection of colorectal cancer stem cell
CN104971070A (en) * 2014-04-04 2015-10-14 北京大学 Oral nano composition of ticagrelor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101229141A (en) * 2008-02-29 2008-07-30 常州制药厂有限公司 Aspirin sustained release tablet and preparing method thereof
CN104971070A (en) * 2014-04-04 2015-10-14 北京大学 Oral nano composition of ticagrelor
CN104950112A (en) * 2015-06-11 2015-09-30 浙江大学 Application of FasL protein serving as biomarker to qualitative Aspirin sensitivity detection of colorectal cancer stem cell

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUILLEM-LLOBT P等: ""Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells"", 《ONCOTARGET》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020188547A1 (en) * 2019-03-21 2020-09-24 Universidade Nova De Lisboa Terpene based therapeutic deep eutectic system, method of obtaining and uses thereof
CN114848654A (en) * 2022-04-18 2022-08-05 武汉大学 Application of aspirin in preparation of medicine for causing tumor immunogenic cell death
CN114848654B (en) * 2022-04-18 2024-04-05 武汉大学 Use of aspirin in the manufacture of a medicament for causing tumor immunogenic cell death

Also Published As

Publication number Publication date
CN108853123B (en) 2020-04-17

Similar Documents

Publication Publication Date Title
Macfarlane et al. Endocrine aspects of argentaffinoma
Ye et al. Poria cocos polysaccharides rescue pyroptosis-driven gut vascular barrier disruption in order to alleviates non-alcoholic steatohepatitis
CN108853123A (en) Application of the aspirin in colon cancerous precaution or treatment
Okuwaki et al. A resected perivascular epithelioid cell tumor (PEComa) of the pancreas diagnosed using endoscopic ultrasound-guided fine-needle aspiration
CN108685921A (en) A kind of application of the quinoline of N isosteres iridin in medicines resistant to liver cancer
CN106290888B (en) Detect antibody compositions and its application of ductal adenocarcinoma of pancreas immunohistochemical markers protein combination
Oyasu et al. Induction of tumors in heterotopic bladder by topical application of N-methyl-N-nitrosourea and N-butyl-N-(3-carboxypropyl) nitrosamine
CN108125974A (en) Application of the tilianin and combinations thereof in anti-angiogenic medicaments are prepared
US20130217902A1 (en) Compounds and pharmaceutical compositions thereof for inhibiting mammalian tumor cell proliferation
CN107213145A (en) Application of the Rabdocetsin B in the product for suppressing esophageal squamous cell cancer cell multiplication is prepared
CN101416979A (en) Use of oligosaccharide in preparing medicine for treating tumor and inhibiting tumor metastasis
Sun et al. Metastatic models of human liver cancer in nude mice orthotopically constructed by using histologically intact patient specimens
CN108714149A (en) Purposes of the garden burnet active constituent in preparing anti-tumor drug
Delarue The free cancer cell
Phung et al. In-vitro and in-vivo assays for angiogenesis-modulating drug discovery and development
Opie THE CAUSES AND VARIETIES OF CHRONIC INTERSTITIAL PANCREATITIS.
CN105534966A (en) Application of gamma-aminobutyric acid as active ingredient for enhancing chemotherapeutic sensitivity
CN105837532A (en) Pharmaceutical composition of benzbromarone and application of pharmaceutical composition in biological medicine
CN109745314A (en) Application of the iron chelating agent Deferasirox (DFX) in the drug for the treatment of cervical carcinoma
CN105879033B (en) II type antagonist of GnRH is inhibiting the application in progestational hormone drug resistance endometrial carcinoma cell proliferation
CN100475227C (en) Antitumor medicine composition and preparing method thereof
CN101513399B (en) Application of T-2 toxin in the preparation of drugs for treating bone cancers and myeloproliferative disorder
CN108272810A (en) Application of the Rhizoma Picrorhizae glucoside II in anti-breast cancer medicines
CN110051734A (en) A kind of pharmaceutical composition and its application of resistive connection enteritis correlation colon cancer
CN110257512A (en) Marker and composition for luminal type and HER2 type breast cancer diagnosis, treatment and prognosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Su Binbin

Inventor after: Zhou Hongxia

Inventor before: Zhou Hongxia

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20200818

Address after: 12-1-302, Yuquan Jiayuan, tiancunshan South Road, Haidian District, Beijing 100049

Patentee after: Su Binbin

Address before: 224100 21 group six, four stoves village, Dafeng grass Temple, Yancheng City, Jiangsu

Patentee before: Zhou Hongxia

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200417